Oct 23 (Reuters) - Sumitovant Biopharma Ltd, along with parent Sumitomo Pharma Co Ltd, has entered into a deal to purchase all shares of Myovant Sciences not already owned by Sumitovant for $27 per share, the companies said in a statement on Sunday. (Reporting by Ann Maria Shibu in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
349 JPY | +0.87% | +18.31% | -25.11% |
May. 14 | Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024 | |
May. 14 | Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.11% | 888M | |
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.64% | 167B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitovant Biopharma to buy Myovant for $27 per share